AMG 076

Drug Profile

AMG 076

Alternative Names: AMG 071 programme; AMG-076; T 71

Latest Information Update: 10 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Anorectics; Benzenesulfonates; Cyclohexanecarboxylic acids; Obesity therapies
  • Mechanism of Action MCHR1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 31 Jul 2008 Discontinued - Phase-I for Obesity in United Kingdom (PO)
  • 13 Aug 2004 Tularik has been acquired and merged into Amgen
  • 24 Feb 2004 Preclinical data have been added to the Obesity pharmacodynamics field (JP Morgan Healthcare Conference 14 January 2004)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top